ArticleEuropean journal of nuclear medicine and molecular imaging2025
Correlation of early-phase β-amyloid positron-emission-tomography and neuropsychological testing in patients with Alzheimer's disease.
Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Modular brain networks shape amyloid-driven tau spread and cognitive decline.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Hypoperfusion in early-phase amyloid PET as a predictor of cognitive decline in Alzheimer's disease.European journal of nuclear medicine and molecular imaging · 2026Article
- Additive value of early-phase β-Amyloid-PET for the differential diagnosis of non-Alzheimer's disease dementia.NeuroImage. Clinical · 2026Article
- Correlation and Interchangeability of Amyloid, Tau, and Glucose Metabolism PET in Mild Cognitive Impairment and Alzheimer: A Review.Brain sciences · 2025Review
- Multi-Modal Deep Clustering Survival Machines for Alzheimer's Disease Subtype Discovery.... IEEE International Conference on Computer Vision workshops. IEEE International Conference on Computer Vision · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeClinical staging in individuals with Alzheimer's disease (AD) typically relies on neuropsychological testing. Recognizing the imperative for an objective measure of clinical AD staging, regional perfusion in early-phase β-amyloid-PET may aid as a cost-efficient index for the assessment of neurodegeneration severity in patients with Alzheimer's disease.
methodsRegional perfusion deficits in early-phase β-amyloid-PET as well as neuropsychological testing (max. 90 days delay) were evaluated in 82 patients with biologically defined AD according to the ATN classification. In reference to the Braak staging system patients were classified into the groups stage
resultsPatients classified as stage
conclusionRegional and global perfusion deficits in early-phase β-amyloid-PET can serve as an objective index of neurodegeneration severity and may act as prognostic markers of future cognitive decline in AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.